| Literature DB >> 31480599 |
Wenwei Han1,2, Lili Song1,2, Yingdi Wang1,2, Youjing Lv1,3, Xiangyan Chen1,2, Xia Zhao4,5,6.
Abstract
Hyaluronic acid (hyaluronan, HA) is a critical component of the extracellular matrix and plays an important biological function of interacting with different molecules and receptors. In this study, both odd- and even-numbered HA oligosaccharides (HAOs) with specific degrees of polymerization (DP) were prepared by different hydrochloric acid hydrolyses, and their structures were characterized by means of HPLC, ESI-MS, and NMR. The data show that the odd-numbered HAOs (DP3-11) have a glucuronic acid reducing end, while the even-numbered HAOs (DP2-10) have an N-acetylglucosamine reducing end. Biological evaluations indicated that all HAOs significantly inhibited the growth and migration of triple-negative breast cancer (TNBC) MDA-MB-231 cells. Among these oligosaccharides, the HA tetrasaccharide (DP4) was confirmed to be the minimum fragment necessary to inhibit MDA-MB-231 cells. Our data suggest that HAOs have potential value in the treatment of TNBC.Entities:
Keywords: hyaluronic acid; oligosaccharides; preparation; structural characterization; triple-negative breast cancer
Mesh:
Substances:
Year: 2019 PMID: 31480599 PMCID: PMC6770828 DOI: 10.3390/biom9090436
Source DB: PubMed Journal: Biomolecules ISSN: 2218-273X
Figure 1Hyaluronic acid oligosaccharide 1 (HAO1) (A) and HAO2 (B) were fractionated by gel exclusion chromatography on a Bio-Gel P10 column.
Summary of the results of ESI-MS and HPLC measurements of HAOs.
| Fraction | Rf a | [M −H]− | [M −2H]2− | [M −3H]3− | [M −4H]4− | Molecular Mass | Purity (%) b |
|---|---|---|---|---|---|---|---|
| DP2 | 0.79 | 396.20 | 397.33 | 99.5 | |||
| DP3 | 0.76 | 572.17 | 285.58 | 573.46 | 98.4 | ||
| DP4 | 0.54 | 775.22 | 387.11 | 776.65 | 99.3 | ||
| DP5 | 0.53 | 475.15 | 316.43 | 952.78 | 98.6 | ||
| DP6 | 0.36 | 576.66 | 384.11 | 1155.79 | 99.5 | ||
| DP7 | 0.32 | 664.71 | 442.81 | 1332.09 | 98.0 | ||
| DP8 | 0.23 | 766.60 | 1535.29 | 99.0 | |||
| DP9 | 0.18 | 854.28 | 569.18 | 426.64 | 1711.41 | 99.4 | |
| DP10 | 0.15 | 956.20 | 637.20 | 1914.61 | 98.8 | ||
| DP11 | 0.11 | 695.56 | 521.42 | 2090.73 | 98.1 |
a Retardation factor (Rf) determined by thin layer chromatography. b Oligosaccharide purity determined by HPLC.
Figure 2The negative-ion ESI-MS/MS profile of DP4 with labeled 1-phenyl-3-methyl-5-pyrazolone (PMP). The ion of m/z 551.17 was selected as the precursor for negative-ion ESI-MS/MS analysis.
Figure 31H NMR spectra of HAOs. (A) DP3, (B) DP4. All samples were previously dissolved in deuterium oxide (D2O, 99.96%) and lyophilized three times to replace exchangeable protons.
Figure 4Preparation of HAOs. The purified HA (~40 kDa) was cleaved with hydrochloric acid at concentrations of 0.1 and 1 mol/L and then fractionated by GPC to obtain the even- and odd-numbered oligosaccharides, respectively.
Figure 5The binding abilities between HAOs and MDA-MB-231. (A) Flow-cytometry histograms showing the ability for the even-numbered HAOs to block HA-fluorescein isothiocyanate (FITC) binding of MDA-MB-231 cells. (B) Fluorescence intensities obtained after competitive binding of even-numbered HAOs during flow-cytometry analysis. (C) The binding abilities of the odd-numbered HAOs. (D) Fluorescence intensities of the odd-numbered HAOs. Data represents the mean ± SD with reference to the HA-FITC group, * p < 0.5, ** p < 0.01, *** p< 0.001; one-way ANOVA with Tukey’s multiple comparisons test.
Figure 6Molecular docking by MOE software of HAOs with receptors. Reasonable binding poses of HA-DP4 in CD44 (A) and TLR4 (B) pockets. Binding energies of HAOs with CD44 (C) and TLR4 (D) pockets. Data represent the mean ± SD with reference to the DP2 group, ** p < 0.01, *** p < 0.001; one-way ANOVA with Tukey’s multiple comparisons test.
Figure 7The migration and growth of MDA-MB-231 induced by HAOs. (A) Scratch width of the control in the presence of HAOs at 100 mmol/L for 48 h. (B) Relative cell viability after 48 h treatment with 100 mmol/L HAOs. Data represent the mean ± SD with reference to the PBS treatment group. * p < 0.05, ** p < 0.01; one-way ANOVA with Tukey’s multiple comparisons test.